CGT 4824
Alternative Names: CGT-4824Latest Information Update: 06 May 2024
At a glance
- Originator Cogent Biosciences
- Class Antineoplastics
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 May 2024 Cogent Biosciences announced its intention to initiate IND-enabling studies for Cancer in 2024 (Cogent Biosciences 10-k, May 2024)
- 07 Dec 2023 Preclinical trials in Cancer in USA (unspecified route)
- 07 Dec 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Cancer released by Cogent Biosciences